- Scarab Genomics has signed an exclusive licensing agreement with Bionova Scientific for the use of a Clean Genome® E. coli strain in plasmid DNA production.
- The agreement allows Bionova to integrate the strain into its pDNA manufacturing workflows to support advanced biologics and genetic medicine programs.
Scarab Genomics said it has entered into an exclusive licensing partnership with Bionova Scientific, granting Bionova rights to use one of Scarab’s proprietary Clean Genome® E. coli strains for plasmid DNA production. The agreement supports pDNA manufacturing for advanced biologics programs.
Under the agreement, Bionova will utilize a Clean Genome strain engineered to remove mobile genetic elements, reduce genomic instability, and minimize non-essential host functions. According to Scarab, these modifications are designed to improve plasmid yields, enhance lot-to-lot consistency, and simplify downstream purification in contract manufacturing processes.
“We’re excited to formalize this partnership with Bionova. Their commitment to supporting innovative therapeutics aligns well with Scarab’s mission to provide high-performance microbial platforms that accelerate development and manufacturing for next-generation biologics.”
Venkat Balakrishnan, PhD, Director of Commercial Operations at Scarab Genomics
The exclusive license enables Bionova to integrate the Clean Genome strain into its plasmid DNA production workflows to support client programs across multiple modalities, including mRNA, viral vectors, and emerging genetic medicine platforms. The companies said the collaboration is intended to strengthen scalable and regulatory-aligned pDNA manufacturing within Bionova’s CDMO and contract manufacturing services.
“Reliable access to high-quality plasmid DNA is critical for many of the programs we support. Scarab’s Clean Genome technology strengthens our ability to deliver consistent, scalable, and regulatory-aligned pDNA manufacturing solutions to our customers.”
Darren Head, President at Bionova Scientific
